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OBJECTIVE: Schizophrenia is associated with increased morbid-
ity and mortality compared to the general population, largely
resulting from increased incidence of cardiovascular disease
and diabetes. Some atypical antipsychotics are associated with
adverse metabolic symptoms, such as weight gain, dyslipidaemia
and glucose dysregulation, which may further increase the risk of
coronary heart disease (CHD) and diabetes. This study aimed to
assess the impact of these symptoms on cost of treating patients’
physical health. METHODS: Data from the Schizophrenia Trial
for Aripiprazole (STAR) study showed that metabolic side effects
of aripiprazole treatment are less than those experienced by
patients receiving standard-of-care (SOC) treatment (physicians’
selection of olanzapine/quetiapine/risperidone). In a post-hoc
analysis, projected risks for diabetes/coronary heart disease
(CHD) were calculated using the Stern and Framingham models.
These risks were used to estimate the difference in direct and
indirect cost consequences of diabetes and CHD in schizophrenia
patients treated with aripiprazole or SOC over a 10-year period,
assuming risk of diabetes onset/CHD events remained linear.
Diabetes costs were estimated from UKPDS and UK T2ARDIS
studies, respectively, and CHD costs were estimated using preva-
lence data from the Health Survey of England and published
literature. All costs were inﬂated to 2007 costs using the UK
government’s Pay and Prices Index inﬂation rates. RESULTS:
The number of avoided diabetes cases (23.4 cases/1000 treated
patients) in patients treated with aripiprazole compared with
SOC was associated with estimated total (direct and indirect)
cost savings of 37,261,293 over ten years for the UK popula-
tion. Similarly, the number of avoided CHD events (3.9 events/
1000 treated patients) was associated with estimated total cost
savings of 7,506,770 over ten years. CONCLUSION: Com-
pared with SOC, the favourable metabolic proﬁle of aripiprazole
treatment may provide reductions in health and economic
burden to schizophrenia patients and psychiatric health care
services in the UK.
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OBJECTIVE: To review the economic burden of Generalized
Anxiety Disorder (GAD) by examining published North Ameri-
can studies and to use this information to deﬁne burden and cost
of illness among patients with GAD. METHODS: A systematic
review of the literature was conducted using a PICO (Population,
Intervention, Comparison, Outcomes) form to guide the search
strategy. MEDLINE, EMBASE, and Cochrane Library databases,
and selected websites, were examined. The search was limited to
papers published in English between 1987 and 2007. Studies
examining outcomes from mixed patient populations, com-
bination therapies or non-pharmacological interventions were
excluded. RESULTS: The initial search yielded a total of 1999
articles, of which approximately 100 met predetermined inclu-
sion criteria. The studies revealed 12-month prevalence rates
ranging from 1.6–3.0%. GAD prevalence was higher among
females compared with males and generally decreased with age.
Comorbid mental disorders were common among patients with
GAD, particularly depressive disorders, and were highly predic-
tive of GAD onset and persistence. GAD was also associated with
a substantive reduction in health-related quality of life. SF-36
scores in one study were 12–28 points lower among patients with
GAD compared with the general US population (1). The health
care resource utilization costs associated with GAD were consid-
erable, although varying patterns of disease identiﬁcation and
treatment made the extent of this utilization difﬁcult to quantify.
Patients with GAD showed signiﬁcantly higher medical care
charges ($2375 vs. $1448, P = 0.006) than patients without
GAD (2). CONCLUSION: GAD, along with other anxiety dis-
orders, exerts substantial cost-related burdens on society, driven
in part by under-recognition and under-treatment of the disorder.
Increased awareness, evidence-based treatment selection and
appropriate early intervention could help to alleviate this burden.
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OBJECTIVE: Patients with bipolar disorder are vulnerable to
developing metabolic illnesses such as hypertension, dyslipi-
demia, and type 2 diabetes mellitus. In addition, mood stabiliz-
ers, anticonvulsants, and antipsychotic medications, which are
commonly used to treat bipolar disorder, have been linked to risk
for adverse metabolic changes. This study uses a large insurance
claims database to examine the prevalence and costs of metabolic
conditions among patients with a bipolar diagnosis relative to
a matched non-bipolar sample. METHODS: A retrospective
analysis was conducted of medical service and prescription
claims from the Thomson Health care MarketScan® Commer-
cial Database (includes claims information on more than 12
million employees with employer-based insurance and their
dependents in the United States). Claims data for 28,531 patients
with bipolar disorder were compared over one year with data for
85,593 age and gender 1–3: matched control patients with no
mental health disorders and no psychotropic medication use. The
prevalence and health care costs of metabolic conditions in
bipolar patients were compared with those of their matched
controls. RESULTS: The bipolar cohort had signiﬁcantly higher
overall medical service and prescription drug costs than the
control cohort ($12,764 versus $3,140, p < 0.0001). Bipolar
patients had a signiﬁcantly higher prevalence of metabolic
co-morbidities than the general population (37% versus 30%,
p < 0.0001), and medical service treatment costs for metabolic
conditions were twice that of the control cohort ($531 versus
$233, p < 0.0001). Prescription medication costs for metabolic
conditions were higher as well, with bipolar cohort per-patient
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costs of $571 versus $301 for the control cohort (p < 0.0001).
CONCLUSION: Bipolar patients have signiﬁcantly more meta-
bolic co-morbidities and higher medical costs than in age- and
gender-matched controls. To reduce the medical and economic
burden of bipolar disorder, strategies should be identiﬁed to
prevent the development of metabolic co-morbidities and
improve medication adherence.
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OBJECTIVE: Obesity, a known risk factor associated with
bipolar disorder, complicates its treatment, potentially adding
signiﬁcantly to overall treatment cost. The difference in bipolar
treatment cost between obese patients and normal weight
patients has not been adequately evaluated. The purpose of this
study is to assess treatment costs and co-morbidities associated
with obesity in Medicaid patients with bipolar disorder.
METHODS: From a multi-state managed care Medicaid claims
database, a total of 13,242 patients with bipolar disorder during
the period January 1, 1998 to December 31, 2002 were selected
for this study. Patients had to be older than six years or younger
than 65 at the ﬁrst date of bipolar diagnosis. Annual treatment
cost per patient was constructed as the sum of reimbursed
amounts (in 2002 constant dollars) for hospitalizations, physi-
cian encounters, drugs, and other medical services. A log-linear
regression analysis was used to assess factors inﬂuencing annual
treatment costs. Logistic regression analysis was conducted to
assess the association between overweight and related clinical
factors. RESULTS: A total of 3192 (24.1%) were treated with
atypical antipsychotics, 1700 (12.8%) with lithium, and 4575
(34.5%) with other anticonvulsants. A total of 1064 (8.0%)
patients received an obesity or overweight diagnosis during the
study period. The average annual treatment costs were $11,780
(SD  15,290) for patients experiencing obesity and $8546
(SD  17,971) otherwise. Other major determinants of higher
treatment cost included bipolar I or NOS (p < 0.0001), being
female (p < 0.0001), the use of anticonvulsants (p < 0.0001) and
atypical antipsychotics (p < 0.0001), alcohol and substance
abuse disorder (p < 0.0001), and diabetes mellitus (p < 0.0001).
The risk of being overweight was statistically associated with
co-morbidities like anxiety disorder (odds ratio [OR] = 1.43,
95% CI: 1.25–1.64), hypertension (OR = 3.02, 95% CI: 2.54–
3.59), etc. CONCLUSION: Signiﬁcant treatment costs are asso-
ciated with obesity in patients with bipolar disorder. Metabolic
complications should be considered by clinical practitioners
when prescribing medication in this population.
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OBJECTIVE: Fewer than half of patients diagnosed with Major
Depressive Disorder (MDD) respond to the ﬁrst medication used,
but an adequate trial may take seven weeks. The BRITE-MD
study reported that a frontal quantitative EEG biomarker, Anti-
depressant Treatment Response [ATR] Index, was 74% accurate
in predicting response/no-response to escitalopram after 1 week
of treatment. The objective is to examine the economic and
quality of life consequences of early switching of medication.
METHODS: We modeled the economic and quality of life con-
sequences of using ATR to individualize treatment of MDD as a
mixed decision tree-Markov model using the seven week results
from the BRITE-MD study. Other potential beneﬁts of the tech-
nology, such as improved adherence, were not considered in this
analysis. RESULTS: The short-term model estimated an increase
of 7.1 responders at seven weeks per 100 treated patients. Based
on published utility weights for responders ranging from 0.73 to
0.78, and an average utility weight for non-responders of 0.47,
the model estimated a 10% gain in QALYs for the ATR group
over the initial 7 weeks of treatment. The incremental cost effec-
tiveness ratio for the base estimate was $11,441. Sensitivity
analysis indicated that ATR was cost saving at modest unit cost
values, and that the $50,000/QALY threshold was not reached
until the unit cost reached $179. Long-term model estimates, and
the cost effectiveness of ATR use under different treatment and
cost assumptions, along with optimized ATR performance, will
also be presented. CONCLUSION: The modeling estimates indi-
cate that the use of ATR would be a cost effective method for
individualizing care for patients with MDD. Under the assump-
tions and cost weights used in our short-term model, ATR fell
well below the $50,000 per QALY threshold for all reasonable
model assumptions, and thus met the usual benchmark for good
value for money for US economic analyses.
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OBJECTIVE: To evaluate impact of risperidone long-acting
injection (RLAI) versus oral antipsychotic treatments on hospi-
talization outcomes for patients participating in the electronic
Schizophrenia Treatment Adherence Registry (e-STAR) in Spain.
METHODS: e-STAR is a two year, multi-national, prospective,
observational study of patients with schizophrenia who were
initiated on RLAI or an oral antipsychotic. This report is based
on the ﬁnal, complete e-STAR data from Spain. Hospitalization
outcomes including number of hospitalizations and number of
days in hospital were collected retrospectively for one year and
prospectively every three months for two years. Changes in hos-
pital stays and days in hospital were compared between RLAI
patients and oral patients using a linear mixed model controlling
for age, gender, disease duration, and baseline antipsychotic use
patterns. RESULTS: A total of 1622 patients (63.6% male, mean
age 38.4  11.2 years) participated in e-STAR from Spain, 1345
were initiated on RLAI and 277 were treated with oral antipsy-
chotics. RLAI patients had signiﬁcantly longer disease duration
(12.6  9.5 years vs. 10.9  9.7 in oral patients, p < 0.01).
Average hospital stay at baseline was ﬁve days longer for RLAI
patients than oral patients. During the two year study, both
treatments showed reductions in mean number of hospitaliza-
tions and mean number of days in hospital. As revealed by
the mixed-model regression, RLAI patients, compared to oral
patients, had a signiﬁcantly greater reduction in mean number of
hospitalizations (-0.28 vs. -0.18 in followup-year1 and -0.37 vs.
-0.20 in followup-year2, p < 0.05) and mean number of days in
hospital (-17.23 vs. -12.96 in followup-year1 and -18.75 vs.
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